A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer

BACKGROUND: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy. METHODS: In this single-center, open-label, dose-escalating phase I trial, p...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Chin J Cancer Res
मुख्य लेखकों: Zhao, Jun, Zhuo, Minglei, Wang, Zhijie, Duan, Jianchun, Wang, Yuyan, Wang, Shuhang, An, Tongtong, Wu, Meina, Wang, Jie
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AME Publishing Company 2016
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4779759/
https://ncbi.nlm.nih.gov/pubmed/27041923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2016.02.07
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन